ATE524547T1 - Einzelsträngige oligonukleotide, welche komplementär zu repetitiven elementen sind, zur behandlung von dns-wiederholungen-instabilitäts- assoziierten erkrankungen - Google Patents
Einzelsträngige oligonukleotide, welche komplementär zu repetitiven elementen sind, zur behandlung von dns-wiederholungen-instabilitäts- assoziierten erkrankungenInfo
- Publication number
- ATE524547T1 ATE524547T1 AT07808532T AT07808532T ATE524547T1 AT E524547 T1 ATE524547 T1 AT E524547T1 AT 07808532 T AT07808532 T AT 07808532T AT 07808532 T AT07808532 T AT 07808532T AT E524547 T1 ATE524547 T1 AT E524547T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- instability
- single stranded
- associated diseases
- stranded oligonucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Neurosurgery (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06118809 | 2006-08-11 | ||
EP06119247 | 2006-08-21 | ||
PCT/NL2007/050399 WO2008018795A1 (en) | 2006-08-11 | 2007-08-10 | Methods and means for treating dna repeat instability associated genetic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE524547T1 true ATE524547T1 (de) | 2011-09-15 |
Family
ID=38668759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07808532T ATE524547T1 (de) | 2006-08-11 | 2007-08-10 | Einzelsträngige oligonukleotide, welche komplementär zu repetitiven elementen sind, zur behandlung von dns-wiederholungen-instabilitäts- assoziierten erkrankungen |
Country Status (16)
Country | Link |
---|---|
US (5) | US20100184833A1 (de) |
EP (1) | EP2049664B1 (de) |
JP (2) | JP6047270B2 (de) |
AT (1) | ATE524547T1 (de) |
AU (1) | AU2007282224B2 (de) |
CA (1) | CA2660523C (de) |
CY (1) | CY1111975T1 (de) |
DK (1) | DK2049664T3 (de) |
ES (1) | ES2373246T3 (de) |
HK (1) | HK1130510A1 (de) |
IL (1) | IL196921A (de) |
NZ (1) | NZ574807A (de) |
PL (1) | PL2049664T3 (de) |
PT (1) | PT2049664E (de) |
SI (1) | SI2049664T1 (de) |
WO (1) | WO2008018795A1 (de) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004097017A2 (en) | 2003-04-29 | 2004-11-11 | Avi Biopharma, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
EP2428227B1 (de) | 2006-01-26 | 2016-06-22 | Ionis Pharmaceuticals, Inc. | Zusammensetzung und deren Verwendungen in Bezug auf Huntingtin |
SI2049664T1 (sl) | 2006-08-11 | 2012-04-30 | Prosensa Technologies Bv | Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev |
JP5926475B2 (ja) * | 2006-09-21 | 2016-05-25 | ユニバーシティー オブ ロチェスター | 筋緊張性ジストロフィーのためのタンパク質置換治療に関する組成物および方法 |
US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
JP2010533170A (ja) | 2007-07-12 | 2010-10-21 | プロセンサ テクノロジーズ ビー.ブイ. | 化合物を種々の選択された臓器、組織又は腫瘍細胞に標的化するための分子 |
JP5600064B2 (ja) | 2007-10-26 | 2014-10-01 | アカデミシュ ジーケンハウス ライデン | 筋障害を相殺するための手段と方法 |
AU2009210872A1 (en) * | 2008-02-08 | 2009-08-13 | Prosensa Holding Bv | Methods and means for treating DNA repeat instability associated genetic disorders |
EP2119783A1 (de) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel |
CA2732343C (en) | 2008-07-29 | 2017-05-09 | The Board Of Regents Of The University Of Texas System | Selective inhibition of polyglutamine protein expression |
US20120149756A1 (en) * | 2009-04-10 | 2012-06-14 | Associatin Institut de Myologie | Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease |
CA2759899A1 (en) | 2009-04-24 | 2010-10-28 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
BR112012005448B1 (pt) | 2009-09-11 | 2021-09-14 | Ionis Pharmaceuticals, Inc | Oligonucleotídeo modificado de fita simples direcionado a um ácido nucleico que codifica huntingtina e capaz de inibir expressão de huntingtina, composição compreendendo o mesmo e seu uso para prevenir, tratar, melhorar, e reduzir a taxa de progressão da doença de huntington |
JP2013518603A (ja) * | 2010-02-08 | 2013-05-23 | アイシス ファーマシューティカルズ, インコーポレーテッド | 反復伸張に関連する疾患または病態の治療に有用な方法および組成物 |
BR112012031363A2 (pt) | 2010-05-28 | 2021-10-26 | Sarepta Therapeutcs, Inc | Análogos de oligonucleotídeo tendo ligações intersubunidades modificadas e/ou grupos terminais. |
EP3633038A3 (de) * | 2010-07-19 | 2020-07-29 | Ionis Pharmaceuticals, Inc. | Modulation der expression der dystrophia-myotonica-proteinkinase (dmpk) |
CA2807187C (en) | 2010-08-05 | 2019-06-11 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins. |
US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
US9476043B2 (en) | 2011-04-08 | 2016-10-25 | Rula Zain-Luqman | Diagnosis and treatment of friedreich's ataxia |
WO2012144906A1 (en) * | 2011-04-22 | 2012-10-26 | Prosensa Technologies B.V. | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1) |
EP2704749A1 (de) | 2011-05-05 | 2014-03-12 | Sarepta Therapeutics, Inc. | Peptid-oligonukleotidkonjugate |
US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
EP4269584A3 (de) | 2011-08-11 | 2024-03-27 | Ionis Pharmaceuticals, Inc. | Selektive antisense-verbindungen und verwendungen davon |
EP2751269B1 (de) | 2011-08-29 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Verfahren und verbindungen für erkrankungen im zusammenhang mit repeat-expansion |
AU2012340390B2 (en) | 2011-11-18 | 2016-11-24 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
US10066228B2 (en) * | 2011-11-30 | 2018-09-04 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
CA2857664A1 (en) | 2011-11-30 | 2013-06-06 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides targeting within the smn2 pre-mrna for use ininduced exon inclusion in spinal muscle atrophy |
BR112014018427B1 (pt) | 2012-01-27 | 2021-11-03 | Biomarin Technologies B.V. | Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker |
US20140378533A1 (en) | 2012-02-08 | 2014-12-25 | Isis Pharmaceuticals, Inc. | Modulation of rna by repeat targeting |
MX358497B (es) | 2012-03-20 | 2018-08-23 | Sarepta Therapeutics Inc | Conjugados de acido boronico de analogos de nucleotido. |
CN104271741A (zh) | 2012-04-23 | 2015-01-07 | 普罗森萨科技有限公司 | 用于治疗神经肌肉障碍的具有改善特性的rna调节寡核苷酸 |
EP3027617A4 (de) | 2013-07-31 | 2017-04-12 | Ionis Pharmaceuticals, Inc. | Verfahren und verbindungen für erkrankungen im zusammenhang mit repeat-expansion |
TW201536329A (zh) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
EP3033425A4 (de) * | 2013-08-16 | 2017-07-26 | Rana Therapeutics, Inc. | Zusammensetzungen und verfahren zur modulation der expression von frataxin |
CA2921459A1 (en) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Oligonucleotides targeting euchromatin regions of genes |
MX2016004452A (es) * | 2013-10-07 | 2017-04-27 | Academisch Ziekenhuis Leiden | Oligonucleotido antisentido dirigido a la eliminacion de sitios de escisión proteolitica, la mutacion de hchwa-d y de expansiones de repeticiones de trinucleotidos. |
WO2015143245A1 (en) * | 2014-03-19 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Methods for modulating ataxin 2 expression |
EP3119888B1 (de) | 2014-03-19 | 2021-07-28 | Ionis Pharmaceuticals, Inc. | Zusammensetzungen zur modulierung der ataxin-2-expression |
WO2016088797A1 (ja) * | 2014-12-02 | 2016-06-09 | 国立大学法人東京医科歯科大学 | Alsの原因タンパク毒性を軽減する核酸 |
US10758558B2 (en) | 2015-02-13 | 2020-09-01 | Translate Bio Ma, Inc. | Hybrid oligonucleotides and uses thereof |
GB201504124D0 (en) | 2015-03-11 | 2015-04-22 | Proqr Therapeutics B V | Oligonucleotides |
US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
MA42695A (fr) | 2015-08-28 | 2018-07-04 | Sarepta Therapeutics Inc | Oligomères antisens modifiés pour l'inclusion d'exons dans l'atrophie musculaire spinale |
US10760076B2 (en) | 2015-10-05 | 2020-09-01 | Proqr Therapeutics Ii B.V. | Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion |
MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
CN110381943A (zh) | 2016-08-12 | 2019-10-25 | 儿童医院 | 用于治疗与重复不稳定性相关的疾病的方法 |
HRP20220943T1 (hr) | 2016-12-19 | 2022-10-28 | Sarepta Therapeutics, Inc. | Oligomerni konjugati koji preskaču egzon za mišićnu distrofiju |
WO2018129384A1 (en) | 2017-01-06 | 2018-07-12 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
US10934547B2 (en) | 2017-02-20 | 2021-03-02 | Northwestern University | Use of trinucleotide repeat RNAs to treat cancer |
GB2574769A (en) | 2017-03-03 | 2019-12-18 | Univ California | RNA Targeting of mutations via suppressor tRNAs and deaminases |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
MX2020005860A (es) | 2017-12-06 | 2020-09-09 | Avidity Biosciences Inc | Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica. |
EP4257128A3 (de) * | 2018-04-11 | 2023-11-15 | Design Therapeutics, Inc. | Verfahren und zusammensetzungen zur behandlung von genetischen erkrankungen |
MX2021000922A (es) | 2018-07-25 | 2021-03-31 | Ionis Pharmaceuticals Inc | Compuestos y metodos para reducir la expresion de la atxn2. |
CA3108289A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
KR102630499B1 (ko) | 2018-12-21 | 2024-01-30 | 어비디티 바이오사이언시스 인크. | 항트랜스페린 수용체 항체 및 이의 용도 |
CA3143071A1 (en) | 2019-07-26 | 2021-02-04 | Proqr Therapeutics Ii B.V. | Ophthalmic compositions comprising viscosifying polymers and nucleic acids |
WO2021113270A1 (en) | 2019-12-02 | 2021-06-10 | Shape Therapeutics Inc. | Therapeutic editing |
EP4121063A1 (de) | 2020-03-19 | 2023-01-25 | Avidity Biosciences, Inc. | Zusammensetzungen und verfahren zur behandlung von fazioskapulohumeraler muskeldystrophie |
CN115697418A (zh) | 2020-03-27 | 2023-02-03 | 艾维迪提生物科学公司 | 治疗肌营养不良的组合物和方法 |
CA3173015A1 (en) | 2020-03-30 | 2021-10-07 | Danith H. Ly | Modified peptide nucleic acid compositions |
EP4151237A1 (de) | 2020-05-12 | 2023-03-22 | Mitsubishi Tanabe Pharma Corporation | Verbindung, verfahren und pharmazeutische zusammensetzung zur regulierung der expression von ataxin 3 |
EP4247392A1 (de) * | 2020-06-03 | 2023-09-27 | Takeda Pharmaceuticals U.S.A., Inc. | Verfahren zur behandlung von nukleotidverstärkungserkrankungen im zusammenhang mit msh3-aktivität |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
WO2023034870A2 (en) | 2021-09-01 | 2023-03-09 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing dmpk expression |
US11912779B2 (en) | 2021-09-16 | 2024-02-27 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
Family Cites Families (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5541308A (en) * | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
DE3834636A1 (de) | 1988-10-11 | 1990-04-19 | Max Planck Gesellschaft | Verfahren zur analyse von laengenpolymorphismen in dna-bereichen |
US5766847A (en) | 1988-10-11 | 1998-06-16 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Process for analyzing length polymorphisms in DNA regions |
US6867195B1 (en) * | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
FR2675803B1 (fr) * | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
EP0558697A1 (de) | 1991-06-28 | 1993-09-08 | Massachusetts Institute Of Technology | Lokale oligonukleotiden Behandlung |
JPH07501204A (ja) | 1991-06-28 | 1995-02-09 | マサチューセッツ インスティテュート オブ テクノロジー | 局所的オリゴヌクレオチド療法 |
US6200747B1 (en) | 1992-01-28 | 2001-03-13 | North Shore University Hospital Research Corp. | Method and kits for detection of fragile X specific, GC-rich DNA sequences |
US5869252A (en) | 1992-03-31 | 1999-02-09 | Abbott Laboratories | Method of multiplex ligase chain reaction |
US6172208B1 (en) * | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
US5418139A (en) | 1993-02-10 | 1995-05-23 | University Of Iowa Research Foundation | Method for screening for cardiomyopathy |
CA2116280A1 (en) | 1993-03-05 | 1994-09-06 | Marcy E. Macdonald | Huntingtin dna, protein and uses thereof |
ATE368107T1 (de) * | 1993-05-11 | 2007-08-15 | Univ North Carolina | Antisense oligonukleotide die anomales splicing verhindern und deren verwendung |
US5695933A (en) | 1993-05-28 | 1997-12-09 | Massachusetts Institute Of Technology | Direct detection of expanded nucleotide repeats in the human genome |
US5741645A (en) | 1993-06-29 | 1998-04-21 | Regents Of The University Of Minnesota | Gene sequence for spinocerebellar ataxia type 1 and method for diagnosis |
US5627263A (en) | 1993-11-24 | 1997-05-06 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
DE4342605A1 (de) | 1993-12-14 | 1995-06-22 | Buna Gmbh | Funktionalisierte Olefinhomo- und -copolymere |
US5962332A (en) | 1994-03-17 | 1999-10-05 | University Of Massachusetts | Detection of trinucleotide repeats by in situ hybridization |
AU2360195A (en) | 1994-05-05 | 1995-11-29 | Beckman Instruments, Inc. | Oligonucleotide repeat arrays |
US5968909A (en) * | 1995-08-04 | 1999-10-19 | Hybridon, Inc. | Method of modulating gene expression with reduced immunostimulatory response |
US5854223A (en) | 1995-10-06 | 1998-12-29 | The Trustees Of Columbia University In The City Of New York | S-DC28 as an antirestenosis agent after balloon injury |
US6300060B1 (en) | 1995-11-09 | 2001-10-09 | Dana-Farber Cancer Institute, Inc. | Method for predicting the risk of prostate cancer morbidity and mortality |
AU725262B2 (en) | 1996-02-14 | 2000-10-12 | Isis Pharmaceuticals, Inc. | Sugar-modified gapped oligonucleotides |
JP3950480B2 (ja) | 1996-07-18 | 2007-08-01 | 株式会社エスアールエル | 脊髄小脳変性症2型の原因遺伝子の検出方法及びそのためのプライマー |
CA2241173A1 (en) | 1996-10-30 | 1998-05-07 | Srl, Inc. | Cdna fragment of causative gene of spinocerebellar ataxia type 2 |
US5853995A (en) | 1997-01-07 | 1998-12-29 | Research Development Foundation | Large scale genotyping of diseases and a diagnostic test for spinocerebellar ataxia type 6 |
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO1998049345A1 (en) | 1997-04-29 | 1998-11-05 | Trustees Of Boston University | Methods and compositions for targeted dna differential display |
US6329501B1 (en) | 1997-05-29 | 2001-12-11 | Auburn University | Methods and compositions for targeting compounds to muscle |
US6280938B1 (en) | 1997-08-19 | 2001-08-28 | Regents Of The University Of Minnesota | SCA7 gene and method of use |
US6514755B1 (en) | 1998-08-18 | 2003-02-04 | Regents Of The University Of Minnesota | SCA7 gene and methods of use |
US6794499B2 (en) * | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
US6130207A (en) | 1997-11-05 | 2000-10-10 | South Alabama Medical Science Foundation | Cell-specific molecule and method for importing DNA into a nucleus |
JP3012923B2 (ja) | 1998-01-26 | 2000-02-28 | 新潟大学長 | Cagリピート病の治療薬 |
KR100280219B1 (ko) | 1998-02-26 | 2001-04-02 | 이수빈 | 삼핵산 반복 서열을 이용한 신경정신 질환의 진단 방법 및 진단 시약 |
US6322978B1 (en) | 1998-04-20 | 2001-11-27 | Joslin Diabetes Center, Inc. | Repeat polymorphism in the frataxin gene and uses therefore |
US6924355B2 (en) * | 1998-09-01 | 2005-08-02 | Genentech, Inc. | PRO1343 polypeptides |
US5945290A (en) | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
CA2343934A1 (en) | 1998-09-25 | 2000-04-06 | The Children's Medical Center Corporation | Short peptides which selectively modulate the activity of protein kinases |
US6210892B1 (en) * | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
US6399575B1 (en) * | 1998-11-10 | 2002-06-04 | Auburn University | Methods and compositions for targeting compounds to the central nervous system |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
US20020049173A1 (en) * | 1999-03-26 | 2002-04-25 | Bennett C. Frank | Alteration of cellular behavior by antisense modulation of mRNA processing |
US6379698B1 (en) | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
JP2000325085A (ja) | 1999-05-21 | 2000-11-28 | Masafumi Matsuo | デュシェンヌ型筋ジストロフィー治療剤 |
US20030236214A1 (en) | 1999-06-09 | 2003-12-25 | Wolff Jon A. | Charge reversal of polyion complexes and treatment of peripheral occlusive disease |
AU5625500A (en) | 1999-06-18 | 2001-01-09 | Emory University | Huntington disease cellular model: stably transfected pc12 cells expressing mutant huntingtin |
WO2005019453A2 (en) | 2001-05-18 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
EP1133993A1 (de) | 2000-03-10 | 2001-09-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Verbingungen zur Behandlung der spinalen Muskelatrophie |
WO2001079283A1 (en) | 2000-04-13 | 2001-10-25 | University Of British Columbia | Modulating cell survival by modulating huntingtin function |
US6653467B1 (en) | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
DE60139394D1 (de) | 2000-04-28 | 2009-09-10 | Asklepios Biopharmaceutical In | Für das dystrophin-minigen kodierende dna-sequenzen und verfahren zu deren verwendung |
EP1278761B1 (de) | 2000-05-01 | 2005-04-06 | Hybridon, Inc. | Modulation von oligonukleotid cpg-vermittelter immunstimulation durch modifikation der nucleoside |
AU2001259706A1 (en) * | 2000-05-09 | 2001-11-20 | Reliable Biopharmaceutical, Inc. | Polymeric compounds useful as prodrugs |
ATE464378T1 (de) * | 2000-05-31 | 2010-04-15 | Serono Genetics Inst Sa | Verwendung des globulären kopfes von acrp30 zur verstärkung der zunahme von muskelmasse und - differenzierung |
CN1326990A (zh) | 2000-06-07 | 2001-12-19 | 上海博德基因开发有限公司 | 一种新的多肽——人类dna cgg重复结合蛋白16.17和编码这种多肽的多核苷酸 |
US20030124523A1 (en) | 2000-06-22 | 2003-07-03 | Asselbergs Fredericus Alphonsus Maria | Organic compounds |
US6794192B2 (en) | 2000-06-29 | 2004-09-21 | Pfizer Inc. | Target |
RU2165149C1 (ru) | 2000-07-03 | 2001-04-20 | Шапошников Валерий Геннадьевич | Система формования и упаковки изделий из сахарной ваты |
US6727355B2 (en) * | 2000-08-25 | 2004-04-27 | Jcr Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treatment of Duchenne muscular dystrophy |
EP1191097A1 (de) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induktion von "exon-skipping" in eukaryotischen Zellen |
US6869777B2 (en) | 2000-10-06 | 2005-03-22 | Regents Of The University Of Michigan | Mini-dystrophin nucleic acid sequences |
CA2427061A1 (en) | 2000-10-27 | 2002-08-01 | Baylor College Of Medicine | Methods and compositions for the identification and treatment of neurodegenerative disorders |
US6623927B1 (en) | 2000-11-08 | 2003-09-23 | Council Of Scientific And Industrial Research | Method of detection of allelic variants of SCA2 gene |
AU2002236499A1 (en) * | 2000-11-30 | 2002-06-11 | Uab Research Foundation | Receptor-mediated uptake of peptides that bind the human transferrin receptor |
US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
TW200526779A (en) * | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
WO2002092763A2 (en) * | 2001-05-11 | 2002-11-21 | Regents Of The University Of Minnesota | Intron associated with myotonic dystrophy type 2 and methods of use |
US20050277133A1 (en) * | 2001-05-18 | 2005-12-15 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20050014172A1 (en) * | 2002-02-20 | 2005-01-20 | Ivan Richards | RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA) |
US20050282188A1 (en) * | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
IL143379A (en) | 2001-05-24 | 2013-11-28 | Yissum Res Dev Co | Oligonucleotide against human ache isoform r and its uses |
NZ530360A (en) | 2001-07-06 | 2006-01-27 | Topigen Pharma Inc | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals by substituting an adenosine base for 2'6'-diaminopurine (DAP) and analogs thereof |
EP1423537A4 (de) * | 2001-08-07 | 2006-11-29 | Univ Delaware | Zusammensetzungen und verfahren zur vorbeugung und behandlung von morbus huntington |
CA2455336A1 (en) | 2001-08-10 | 2003-02-20 | Novartis Ag | Peptides that bind to atherosclerotic lesions |
US20060074034A1 (en) * | 2001-09-17 | 2006-04-06 | Collins Douglas A | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof |
KR20030035047A (ko) | 2001-10-29 | 2003-05-09 | (주)바이오코돈 | Bmp-4 유전자 발현을 이용한 편평태선 질환의 치료 및진단방법 |
WO2003037172A2 (en) | 2001-11-01 | 2003-05-08 | Gpc Biotech Inc. | Endothelial-cell binding peptides for diagnosis and therapy |
US20030134790A1 (en) | 2002-01-11 | 2003-07-17 | University Of Medicine And Dentistry Of New Jersey | Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer |
WO2003069330A1 (en) | 2002-02-11 | 2003-08-21 | The Trustees Of Columbia University In The City Of New York | System and method for identifying proteins involved in force-initiated signal transduction |
US20050096284A1 (en) | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
AU2003220011B2 (en) | 2002-03-01 | 2008-05-29 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
US20040101852A1 (en) | 2002-11-21 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of CGG triplet repeat binding protein 1 expression |
ITRM20020253A1 (it) | 2002-05-08 | 2003-11-10 | Univ Roma | Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche. |
EP1380644A1 (de) | 2002-07-08 | 2004-01-14 | Kylix B.V. | Verwendung spezifischer TCF Zielgene zur Identifizierung von Medikamenten zur Behandlung von Krebsarten, insbesondere Colorectalkrebs, bei denen TCF/beta-catenin/WNT Signaltransduktion eine zentrale Rolle spielt |
US7589059B2 (en) | 2002-07-26 | 2009-09-15 | Roche Madison Inc. | Delivery of molecules and complexes to mammalian cells in vivo |
US20050255086A1 (en) | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
US20060058253A1 (en) | 2002-08-12 | 2006-03-16 | Benoit Chabot | Methods to reprogram splice site selection in pre-messenger rnas |
GB0219143D0 (en) | 2002-08-16 | 2002-09-25 | Univ Leicester | Modified tailed oligonucleotides |
WO2004037854A1 (en) | 2002-10-23 | 2004-05-06 | Centre For Research And Technology Hellas/Institute Of Agrobiotechnology In.A | Prion protein-binding peptide sequences |
US7892793B2 (en) | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
EP2284266B1 (de) * | 2002-11-14 | 2013-11-06 | Thermo Fisher Scientific Biosciences Inc. | siRNA Molekül gegen tp53 |
US7655785B1 (en) * | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
ES2566629T3 (es) | 2002-11-25 | 2016-04-14 | Masafumi Matsuo | Fármacos de ácido nucleico ENA que modifican el corte y empalme en precursores de ARNm |
GB0228079D0 (en) | 2002-12-02 | 2003-01-08 | Laxdale Ltd | Huntington's Disease |
EP2216407B1 (de) * | 2003-03-07 | 2016-01-13 | Alnylam Pharmaceuticals, Inc. | Therapeutische Zusammensetzungen |
CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
US7514551B2 (en) * | 2003-04-03 | 2009-04-07 | Enzo Life Sciences, Inc. | Multisignal labeling reagents, and processes and uses therefor |
JP4179562B2 (ja) * | 2003-05-14 | 2008-11-12 | 独立行政法人科学技術振興機構 | ハンチンチン遺伝子の発現抑制 |
WO2004108157A2 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
EP1495769B1 (de) | 2003-07-11 | 2008-02-27 | LBR Medbiotech B.V. | Mannose-6-Phosphat Rezeptor vermittelter Gentransfer zu Muskelzellen |
US20050054752A1 (en) | 2003-09-08 | 2005-03-10 | O'brien John P. | Peptide-based diblock and triblock dispersants and diblock polymers |
US7355018B2 (en) * | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
EP1680439A2 (de) | 2003-10-14 | 2006-07-19 | Kernel Biopharma Inc. | Zweiphasige pna-konjugate zum transport von pna über die blut-hirn-schranke |
US20050191636A1 (en) | 2004-03-01 | 2005-09-01 | Biocept, Inc. | Detection of STRP, such as fragile X syndrome |
WO2005086768A2 (en) | 2004-03-11 | 2005-09-22 | Albert Einstein College Of Medicine Of Yeshiva University | Enhanced production of functional proteins from defective genes |
WO2005105995A2 (en) | 2004-04-14 | 2005-11-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2005116204A1 (ja) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Rna干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
US20100183695A1 (en) | 2004-05-27 | 2010-07-22 | John Knopf | Cerberus/coco derivatives and uses thereof |
DE602005026386D1 (de) * | 2004-06-28 | 2011-03-31 | Univ Western Australia | Antisense-oligonukleotide zur induktion von exon-skipping sowie verfahren zur verwendung davon |
EP1618881A1 (de) | 2004-07-20 | 2006-01-25 | Santhera Pharmaceuticals (Schweiz) GmbH | Verwendung von steroiden ohne glucocorticoid aktivität zur behandlung von muskulärer dystrophie |
WO2006017522A2 (en) | 2004-08-03 | 2006-02-16 | University Of Utah Research Foundation | Use of antisense oligonucleotides to effect translation modulation |
ITRM20040568A1 (it) | 2004-11-18 | 2005-02-18 | Uni Degli Studi Di Roma Tor Vergata | Uso della tecnica "phage display" per l'identificazione di peptidi con capacita' di legame a cellule staminali/progenitore, peptidi cosi' ottenuti e loro usi. |
US7838657B2 (en) * | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
US20120122801A1 (en) | 2005-01-05 | 2012-05-17 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
US20060148740A1 (en) * | 2005-01-05 | 2006-07-06 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
EP1844148A2 (de) | 2005-01-31 | 2007-10-17 | University of Iowa Research Foundation | Nukleinsäure-silencing von huntington-krankheits-genen |
EP1877555A2 (de) | 2005-04-22 | 2008-01-16 | Academisch Ziekenhuis Leiden | Modulation der exon-erkennung in prä-mrna durch störung der bindung von sr-proteinen und durch störung der rna-sekundärstruktur |
US7906617B2 (en) * | 2005-12-15 | 2011-03-15 | E. I. Du Pont De Nemours And Company | Polyethylene binding peptides and methods of use |
EP2428227B1 (de) | 2006-01-26 | 2016-06-22 | Ionis Pharmaceuticals, Inc. | Zusammensetzung und deren Verwendungen in Bezug auf Huntingtin |
WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
EP1857548A1 (de) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Mittel und Verfahren zur Induktion von Exon-skipping |
CN101501193B (zh) | 2006-08-11 | 2013-07-03 | 普罗森那技术公司 | 用于治疗与dna重复不稳定性相关的遗传病的方法和手段 |
SI2049664T1 (sl) * | 2006-08-11 | 2012-04-30 | Prosensa Technologies Bv | Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev |
JP2010533170A (ja) | 2007-07-12 | 2010-10-21 | プロセンサ テクノロジーズ ビー.ブイ. | 化合物を種々の選択された臓器、組織又は腫瘍細胞に標的化するための分子 |
JP5706157B2 (ja) | 2007-07-12 | 2015-04-22 | プロセンサ テクノロジーズ ビー.ブイ.Prosensa Technologies B.V. | 化合物を種々の選択臓器又は組織に標的化するための分子 |
JP5600064B2 (ja) | 2007-10-26 | 2014-10-01 | アカデミシュ ジーケンハウス ライデン | 筋障害を相殺するための手段と方法 |
AU2009210872A1 (en) | 2008-02-08 | 2009-08-13 | Prosensa Holding Bv | Methods and means for treating DNA repeat instability associated genetic disorders |
EP2119783A1 (de) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel |
US20110218334A1 (en) | 2008-07-11 | 2011-09-08 | Alnylam Pharmaceuticals, Inc. | PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS |
CA2732343C (en) | 2008-07-29 | 2017-05-09 | The Board Of Regents Of The University Of Texas System | Selective inhibition of polyglutamine protein expression |
KR101866152B1 (ko) | 2008-12-04 | 2018-06-08 | 큐알엔에이, 인크. | 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료 |
CA2759899A1 (en) | 2009-04-24 | 2010-10-28 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
MX2011013176A (es) | 2009-06-08 | 2012-04-30 | Miragen Therapeutics | Motivos de modificación química para inhibidores y miméticos del miarn. |
JP6141018B2 (ja) | 2009-12-24 | 2017-06-07 | バイオマリン テクノロジーズ ベー.フェー. | 炎症性障害を治療するための分子 |
JP2013518603A (ja) | 2010-02-08 | 2013-05-23 | アイシス ファーマシューティカルズ, インコーポレーテッド | 反復伸張に関連する疾患または病態の治療に有用な方法および組成物 |
WO2011097614A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Mehods and compositions useful in diseases or conditions related to repeat expansion |
EP3633038A3 (de) | 2010-07-19 | 2020-07-29 | Ionis Pharmaceuticals, Inc. | Modulation der expression der dystrophia-myotonica-proteinkinase (dmpk) |
DK2605794T3 (en) | 2010-08-20 | 2016-10-24 | Replicor Inc | Oligonukleotidchelatkomplekser |
EP3067421B1 (de) | 2011-02-08 | 2018-10-10 | Ionis Pharmaceuticals, Inc. | Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon |
WO2012144906A1 (en) | 2011-04-22 | 2012-10-26 | Prosensa Technologies B.V. | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1) |
EP2704749A1 (de) | 2011-05-05 | 2014-03-12 | Sarepta Therapeutics, Inc. | Peptid-oligonukleotidkonjugate |
US10066228B2 (en) | 2011-11-30 | 2018-09-04 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
BR112014018427B1 (pt) | 2012-01-27 | 2021-11-03 | Biomarin Technologies B.V. | Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker |
US20140378533A1 (en) | 2012-02-08 | 2014-12-25 | Isis Pharmaceuticals, Inc. | Modulation of rna by repeat targeting |
CN104271741A (zh) | 2012-04-23 | 2015-01-07 | 普罗森萨科技有限公司 | 用于治疗神经肌肉障碍的具有改善特性的rna调节寡核苷酸 |
CA2877644A1 (en) | 2012-07-03 | 2014-01-09 | Prosensa Technologies B.V. | Oligonucleotide for the treatment of muscular dystrophy patients |
-
2007
- 2007-08-10 SI SI200730778T patent/SI2049664T1/sl unknown
- 2007-08-10 US US12/377,160 patent/US20100184833A1/en not_active Abandoned
- 2007-08-10 WO PCT/NL2007/050399 patent/WO2008018795A1/en active Application Filing
- 2007-08-10 ES ES07808532T patent/ES2373246T3/es active Active
- 2007-08-10 PL PL07808532T patent/PL2049664T3/pl unknown
- 2007-08-10 AT AT07808532T patent/ATE524547T1/de active
- 2007-08-10 CA CA2660523A patent/CA2660523C/en active Active
- 2007-08-10 DK DK07808532.1T patent/DK2049664T3/da active
- 2007-08-10 PT PT07808532T patent/PT2049664E/pt unknown
- 2007-08-10 EP EP07808532A patent/EP2049664B1/de active Active
- 2007-08-10 JP JP2009523740A patent/JP6047270B2/ja active Active
- 2007-08-10 AU AU2007282224A patent/AU2007282224B2/en active Active
- 2007-08-10 NZ NZ574807A patent/NZ574807A/en unknown
-
2009
- 2009-02-05 IL IL196921A patent/IL196921A/en active IP Right Grant
- 2009-10-20 HK HK09109656.7A patent/HK1130510A1/xx unknown
-
2011
- 2011-10-20 CY CY20111100994T patent/CY1111975T1/el unknown
-
2015
- 2015-03-12 JP JP2015050040A patent/JP5934408B2/ja active Active
- 2015-07-27 US US14/809,483 patent/US9890379B2/en active Active
-
2017
- 2017-12-27 US US15/855,848 patent/US10689646B2/en active Active
-
2019
- 2019-10-22 US US16/660,387 patent/US11274299B2/en active Active
-
2022
- 2022-02-03 US US17/591,681 patent/US20220267765A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20100184833A1 (en) | 2010-07-22 |
HK1130510A1 (en) | 2009-12-31 |
JP6047270B2 (ja) | 2016-12-21 |
CA2660523C (en) | 2019-03-19 |
AU2007282224B2 (en) | 2013-08-29 |
US20200140857A1 (en) | 2020-05-07 |
US11274299B2 (en) | 2022-03-15 |
IL196921A0 (en) | 2011-08-01 |
JP2015157813A (ja) | 2015-09-03 |
NZ574807A (en) | 2011-01-28 |
ES2373246T3 (es) | 2012-02-01 |
AU2007282224A1 (en) | 2008-02-14 |
US10689646B2 (en) | 2020-06-23 |
PT2049664E (pt) | 2012-01-03 |
JP5934408B2 (ja) | 2016-06-15 |
EP2049664B1 (de) | 2011-09-14 |
US20180112214A1 (en) | 2018-04-26 |
WO2008018795A1 (en) | 2008-02-14 |
US9890379B2 (en) | 2018-02-13 |
US20160053254A1 (en) | 2016-02-25 |
IL196921A (en) | 2013-11-28 |
PL2049664T3 (pl) | 2012-02-29 |
EP2049664A1 (de) | 2009-04-22 |
DK2049664T3 (da) | 2012-01-02 |
US20220267765A1 (en) | 2022-08-25 |
CA2660523A1 (en) | 2008-02-14 |
SI2049664T1 (sl) | 2012-04-30 |
JP2010500023A (ja) | 2010-01-07 |
CY1111975T1 (el) | 2015-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE524547T1 (de) | Einzelsträngige oligonukleotide, welche komplementär zu repetitiven elementen sind, zur behandlung von dns-wiederholungen-instabilitäts- assoziierten erkrankungen | |
CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
EP3800255A3 (de) | Rna-geführte transkriptionsregulierung und verfahren zur verwendung davon zur behandlung von rückenschmerzen | |
WO2005079533A3 (en) | Methods and compositions for mediating gene silencing | |
NO20084488L (no) | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | |
WO2009033027A3 (en) | Suppression of scn9a gene expression and/or function for the treatment of pain | |
WO2004022580A3 (en) | Bh3 peptides and method of use thereof | |
WO2010068884A3 (en) | Methods and systems for direct sequencing of single dna molecules | |
WO2008060510A3 (en) | Zinc finger nuclease for targeting the human glucocorticoid receptor locus | |
WO2008070672A3 (en) | Compositions and methods to treat cancer with cupredoxins and cpg rich dna | |
WO2001048190A8 (en) | Therapeutic uses of lna-modified oligonucleotides | |
EP2631294A3 (de) | Menschliche Mikro-RNAs und Verfahren zur Hemmung davon | |
CY1115059T1 (el) | Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα | |
WO2007109097A3 (en) | RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF | |
NZ624783A (en) | Modulation of huntingtin expression | |
WO2008115851A3 (en) | Rnai therapeutic for respiratory virus infection | |
ATE548454T1 (de) | Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis | |
WO2009090639A3 (en) | Sirna compounds and methods of use thereof | |
MX2020012652A (es) | Oligonucleotido bicatenario especifico del gen de anfirregulina y composicion para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo. | |
ATE465261T1 (de) | Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken | |
WO2007149521A3 (en) | Nucleotide motifs providing localization elements and methods of use | |
TW200724679A (en) | Treatment of disease using an improved regulated expression system | |
EP1772152A3 (de) | Zubereitung zur Induktion von Immuntoleranz | |
WO2007124148A3 (en) | Treatment of connective tissue disorders | |
WO2009152500A3 (en) | Methods and compositions for mediating gene silencing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 2049664 Country of ref document: EP |